Menu

Blog

Archive for the ‘life extension’ category: Page 149

Dec 5, 2022

Investing in the Age of Longevity 2022 — Patrick Burgermeister — KIZOO Technology Ventures

Posted by in categories: biotech/medical, business, life extension

Patrick Burgermeister of KIZOO Technology Ventures presents at Investing in the Age of Longevity 2022. In his talk, Patrick gives an overview of KIZOO Technology Ventures’ investment strategy, with a particular focus on misson-driven investments in early stage companies that open new categories of treatment. Patrick showcases six biotech startups that form part of the company’s key investments: Cellvie, Revel, Cyclarity, LIfT BioSciences, Elastrin, and Mogling Bio.

Download the presentation slides: https://bit.ly/IAL22-Patrick-Burgermeister.

Continue reading “Investing in the Age of Longevity 2022 — Patrick Burgermeister — KIZOO Technology Ventures” »

Dec 4, 2022

What Will Happen After The Technological Singularity? — Ray Kurzweil

Posted by in categories: bioengineering, biotech/medical, life extension, nanotechnology, Ray Kurzweil, robotics/AI, singularity, transhumanism

Ray Kurzweil is an author, computer scientist, inventor, futurist and a director of engineering at Google. Kurzweil is a public advocate for the futurist and transhumanist movements, and gives public talks to share his optimistic outlook on life extension technologies and the future of nanotechnology, robotics, and biotechnology.

Recorded 2013

Dec 4, 2022

A Glb1-2A-mCherry reporter monitors systemic aging and predicts lifespan in middle-aged mice Communications

Posted by in categories: biotech/medical, life extension

Aging inevitably increases the risk of disease, as exemplified by CAD, AD, and cancer. Monitoring the aging process and understanding its mechanisms will not only enhance early diagnoses, it may also provide strategies for the early prevention and treatment of diseases. While biomarkers for cellular senescence in in vitro cultured mammalian cells are already well-defined, those that define in vivo senescence/aging at the systemic level remain scarce. Here, we generated a targeted Glb1+/m allele at the Glb1 locus that encodes β-galactosidase. The GAC signal indicates Glb1 level. The results reveal that the live-imaged GAC signal is linearly correlated with chronological age, but only in middle-aged mice (9–13 months). High GAC at the MA stage was associated with cardiac hypertrophy and shortened lifespan. Moreover, GAC signal was exponentially increased in pathological lung fibrosis induced by BLM. Thus, this in vivo reporter mouse can faithfully monitor systemic aging and organ functional decline in a manner closely associated with lifespan, and provides an ideal system for studying aging mechanisms and developing anti-aging manipulations.

The upregulation of p16Ink4a transcription and elevated SAβ-gal staining are both well-established and widely used biomarkers for cellular senescence17, and the former led to the generation of live-imaging aging reporter mice20,22,23. Intriguingly, high level of p16Ink4a, indicated by luciferase activity, predicts cancer initiation rather than lifespan. Similarly, the in vivo application of SAβ-gal as a senescence marker at the tissue level is also limited. Positive SAβ-gal-staining is easy to obtain in kidney and adipose tissue sections but difficult to obtain in blood vessel and heart sections. By SAβ-gal staining, not many positive cells were detected in old individuals26. It raises the question of whether SAβ-gal labels in vivo senescence or if the percentage of in vivo senescent cells is indeed very low.

Dec 4, 2022

Guest speaker Aubrey de Grey, PhD, discuss the possibility of extending life on our channel

Posted by in categories: biotech/medical, life extension

New advances in medical science may improve health of older people and extend lift, perhaps just long enough for more advanced future therapies.#longevity #health #healthspan What is the next step and how can we combine different therapies and test if we can rejuvenate an adult mouse, and humans?Our guest speaker Aubrey de Grey present what may come next.

If you wish to check the links to the sites mentioned in the discussion: https://www.levf.orghealthspanaction.orga4li.orglessdeath.orgTo donate to Longevity Escape Velocity Foundation (LEVF) and to the rejuvenation research:

Continue reading “Guest speaker Aubrey de Grey, PhD, discuss the possibility of extending life on our channel” »

Dec 4, 2022

The Thymus As A Key Target For Aging Intervention — Dr. Greg Fahy — EARD 2022

Posted by in categories: biotech/medical, computing, cryonics, genetics, life extension

This is a followup trial result to the first trial that reported 2.5 years of epigenetic age reversal This has interesting reports from the actual patients about how they feel and the changes it made to them. After the first trial I sent an email to see if I could do this but I have IBS which Fahy said would disqualify me.


Dr. Greg Fahy gives an update on the TRIIM-X clinical trial at EARD 2022.

Continue reading “The Thymus As A Key Target For Aging Intervention — Dr. Greg Fahy — EARD 2022” »

Dec 4, 2022

Methionine Restriction Extends Lifespan: Roles For SCFAs And FGF21, But Not Calorie Restriction

Posted by in categories: biotech/medical, genetics, life extension

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

TruDiagnostic Discount Link (Epigenetic Testing)
CONQUERAGING!
https://bit.ly/3Rken0n.

Continue reading “Methionine Restriction Extends Lifespan: Roles For SCFAs And FGF21, But Not Calorie Restriction” »

Dec 3, 2022

Scientists find a better drug for blinding eye disease in older people

Posted by in categories: biotech/medical, life extension

Age-related macular degeneration (AMD) is the most common cause of vision loss among people aged 50 and older, affecting an estimated 7.3 million individuals in the United States. Of these patients, 1.75 million have advanced AMD and will lose vision from this condition. This includes patients with the “wet” form of AMD, characterized by the growth of abnormal blood vessels in the retina that can bleed or leak damaging fluids into the central portion of this light-sensing tissue.

Dec 3, 2022

Next Generation Therapies For Rejuvenation | Dr Noah Davidsohn Interview Series Ep5/5

Posted by in categories: biotech/medical, life extension

“Our goal is to re-regulate all of your genes back to an earlier state.” Excellent. Hurry please. I’m 51.


Magnesium Break Through 10% Discount https://bit.ly/3O5tPfu.
This video brought to you by BiOptimizers.

Continue reading “Next Generation Therapies For Rejuvenation | Dr Noah Davidsohn Interview Series Ep5/5” »

Dec 2, 2022

World-leading hospital set to specialise in longevity

Posted by in categories: biotech/medical, life extension

One of the world’s leading hospitals is preparing to offer longevity clinical services to patients. Sheba Medical Center in Tel Aviv, Israel, is poised to open a dedicated longevity centre in 2023, with the goal of democratising the extension of healthy lifespan for the masses.

Longevity. Technology: While research, development and investment in longevity are at an all-time high, the implementation of longevity clinical practice in mainstream healthcare is virtually non-existent. While private clinical practices are now making longevity services accessible to those who can afford it, the societal benefit of improving healthspan can only be realised if everyone can access it. To learn more, we caught up with Professor Tzipi Strauss, Director of Neonatology at Sheba Hospital, who is the driving force behind the new centre.

It may seem curious that a paediatrician is the instigator of an initiative focused on improving aging, but Strauss explains that the relevance of longevity begins at birth.

Dec 2, 2022

Cajal Neuroscience launches with $96 million to transform neurodegeneration drug discovery

Posted by in categories: biotech/medical, computing, genetics, life extension, neuroscience

Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, has launched with the completion of a $96 million Series A financing.

The financing was led by The Column Group and Lux Capital, with additional participation from Two Sigma Ventures, Evotec, Bristol Myers Squibb, Alexandria Venture Investments, Dolby Family Ventures and other investors.

Longevity. Technology: Seattle-based Cajal is committed to discovering novel therapeutics for neurodegeneration; by focusing on the mechanistic, spatial and temporal complexity of neurodegeneration, the biotech’s powerful platform is designed to unlock the complexity of disease at unprecedented scale, and integrates expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput functional validation.